Methods, compositions, and kits for treating shiga toxin associated conditions
AssigneeThallion Pharmaceuticals Inc.
InventorsMarc Riviere, Claire Thuning-Roberson, Mariam Mehran, Alison O'Brien, Angela Melton-Celsa, Janique Sam-Pan
Life of this patent
Estimating the term…
Abstract
The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (cαStx1) and anti-Shiga Toxin 2 (cαStx2) antibodies.
Claims16
A method for the treatment of a Shiga toxin associated condition in a subject comprising administering an effective amount of a chimeric anti-Stx1 and a chimeric anti-Stx2 antibody to said subject, wherein each of the chimeric antibodies is administered at 1 mg/kg or 3 mg/kg, wherein said chimeric anti-Stx1 antibody comprises:
- (a) a human IgG1-kappa immunoglobulin constant region;
- (b) an immunoglobulin heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:1;
- and
- (c) an immunoglobulin light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:2;
- and wherein said chimeric anti-Stx2 antibody comprises:
- (d) a human IgG1-kappa immunoglobulin constant region;
- (e) an immunoglobulin heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 3;
- and
- (f) an immunoglobulin light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 4.
An article of manufacture comprising a chimeric anti-Stx1 and a chimeric anti-Stx2 antibody, and a label, wherein said label indicates that said chimeric anti-Stx1 and chimeric anti-Stx2 antibodies are for treating a Shiga-toxin associated disease and are to be administered at a dosage of 1 mg/kg or 3 mg/kg each, wherein said chimeric anti-Stx1 antibody comprises:
- (a) a human IgG1-kappa immunoglobulin constant region;
- (b) an immunoglobulin heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 1;
- and
- (c) an immunoglobulin light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:2;
- and wherein said chimeric anti-Stx2 antibody comprises:
- (d) a human IgG1-kappa immunoglobulin constant region;
- (e) an immunoglobulin heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 3;
- and
- (f) an immunoglobulin light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 4.
A kit comprising a chimeric anti-Stx1 and a chimeric anti-Stx2 antibody, instructions, and a label, wherein said instructions are for administering said chimeric anti-Stx1 and chimeric anti-Stx2 antibodies at a dosage of 1 mg/kg or 3 mg/kg, wherein said label indicates that said chimeric anti-Stx1 and chimeric anti-Stx2 antibodies are for treating a Shiga-toxin associated disease, wherein said chimeric anti-Stx1 antibody comprises:
- (a) a human IgG1-kappa immunoglobulin constant region;
- (b) an immunoglobulin heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 1;
- and
- (c) an immunoglobulin light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:2;
- and wherein said chimeric anti-Stx2 antibody comprises:
- (d) a human IgG1-kappa immunoglobulin constant region;
- (e) an immunoglobulin heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 3;
- and
- (f) an immunoglobulin light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 4.
Dependencies are inferred from the claim text.